arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

CRISPR Therapeutics AG

CRSP Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$55.46
▼ -0.6% Today
as of Sep 4, 16:47 ET
Last 30 days +19.39% Jul 27 → Sep 04
$45.60 $49.71 $53.82 $57.92 $62.03 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$56.06
High
$57.21
Low
$55.35
Volume
$894,604
Avg Vol
$2M
Mkt Cap
$5.2B
P/E (TTM)
—
Beta
—
52w High
$78.48
52w Low
$44.12
Div Yield
—
Shares Out
$97M

Recent Press Releases & News last 60 days · 25 items

Sep 2 · 23:05 Motley Fool
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026
Sep 2 · 21:08 Simply Wall St.
CRISPR Therapeutics (CRSP) Stock Looks Fully Valued As CTX310 Data Impresses
Sep 2 · 15:30 Zacks
Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report?
▸ Show all 25 press releases & news Free account →

Overview

52-week range
$44
$78
33% of range
Avg surprise (last 3)
-8.2%
Avg reaction (last 2)
-4.0%
50% positive
Latest IV / EM
134%
EM ±5.6% · $56 · Sep 4

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.58$-1.35$-1.12$-0.90$-0.67 Actual $-0.67Actual $-0.98Actual $-1.41Actual $-1.43Actual $-1.49Actual $-1.01Actual $-1.58Est $-1.27Actual $-1.29Est $-1.47Actual $-1.17Actual $-1.28Est $-1.14Actual $-0.94 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-209M$-154M$-99M$-44M$11M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.94 — — — — financials
Mon May 4, 2026Mar/2026 $-1.28 $-1.14 -12.3% +19.0% +3.8% earnings
Tue Sep 30, 2025Sep 2025 $-1.17 — — — — financials
Mon Aug 4, 2025Jun/2025 $-1.29 $-1.47 +12.2% — — earnings
Tue May 6, 2025Mar/2025 $-1.58 $-1.27 -24.4% — -11.9% earnings
Mon Sep 30, 2024Sep 2024 $-1.01 — — — — financials
Sun Jun 30, 2024Jun 2024 $-1.49 — — — — financials
Sun Mar 31, 2024Mar 2024 $-1.43 — — — — financials
Sat Sep 30, 2023Sep 2023 $-1.41 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.98 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.67 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$10M$1M—$889,000$892,000$865,000—$602,000
Cost of revenue————————
Gross profit————————
Operating income$-117M$-130M—$-132M$-229M$-148M—$-110M
Net income$-91M$-123M—$-106M$-209M$-136M—$-86M
EPS (diluted)$-0.94$-1.28—$-1.17$-2.40$-1.58—$-1.01

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$291M$423M$348M$286M$194M$235M$298M$226M
Inventory————————
Total current assets$2.37B$2.45B$1.99B$1.93B$1.73B$1.87B$1.94B$1.94B
Total assets$2.65B$2.73B$2.27B$2.25B$2.03B$2.17B$2.24B$2.26B
Long-term debt$586M$585M$0—————
Total liabilities$904M$911M$343M$329M$319M$337M$310M$316M
Total equity$1.75B$1.81B$1.92B$1.92B$1.71B$1.83B$1.93B$1.94B

Implied volatility — last 90 days

37%61%85%109%133% Jun 07 — IV 72% · EM ±6.7%Jun 08 — IV 70% · EM ±5.8%Jun 09 — IV 80% · EM ±5.8%Jun 10 — IV 98% · EM ±5.8%Jun 11 — IV 80% · EM ±3.3%Jun 15 — IV 70% · EM ±5.0%Jun 16 — IV 83% · EM ±4.9%Jun 17 — IV 103% · EM ±4.3%Jun 19 — IV 58% · EM ±6.4%Jun 22 — IV 64% · EM ±5.4%Jun 23 — IV 51% · EM ±3.7%Jun 24 — IV 70% · EM ±4.2%Jun 25 — IV 84% · EM ±3.5%Jun 29 — IV 62% · EM ±14.7%Jun 30 — IV 59% · EM ±13.8%Jul 01 — IV 81% · EM ±3.4%Jul 03 — IV 79% · EM ±8.7%Jul 06 — IV 82% · EM ±6.8%Jul 07 — IV 53% · EM ±3.8%Jul 08 — IV 104% · EM ±6.2%Jul 09 — IV 55% · EM ±2.3%Jul 13 — IV 87% · EM ±7.3%Jul 14 — IV 73% · EM ±5.3%Jul 15 — IV 82% · EM ±4.9%Jul 16 — IV 127% · EM ±5.3%Jul 20 — IV 63% · EM ±5.3%Jul 21 — IV 75% · EM ±5.4%Jul 22 — IV 59% · EM ±3.5%Jul 23 — IV 42% · EM ±1.8%Jul 27 — IV 80% · EM ±6.7%Jul 28 — IV 89% · EM ±6.4%Jul 29 — IV 85% · EM ±5.0%Jul 30 — IV 75% · EM ±3.1%Aug 03 — IV 109% · EM ±9.1%Aug 04 — IV 38% · EM ±2.7%Aug 05 — IV 69% · EM ±4.1%Aug 06 — IV 80% · EM ±3.4%Aug 10 — IV 64% · EM ±5.3%Aug 11 — IV 56% · EM ±4.0%Aug 12 — IV 55% · EM ±3.2%Aug 13 — IV 75% · EM ±3.1%Aug 18 — IV 55% · EM ±4.0%Aug 19 — IV 86% · EM ±5.1%Aug 20 — IV 93% · EM ±3.9%Aug 24 — IV 82% · EM ±6.9%Aug 25 — IV 56% · EM ±4.1%Aug 26 — IV 74% · EM ±4.4%Aug 27 — IV 117% · EM ±4.9%Aug 31 — IV 56% · EM ±4.7%Sep 01 — IV 95% · EM ±6.9%Sep 02 — IV 58% · EM ±3.4%Sep 03 — IV 134% · EM ±5.6%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in